The current study demonstrated that treatment with an anti-CXCL13 neutralizing antibody attenuated behavioral deficits in lupus-prone mice and could be doing so on a molecular level by altering expression levels of certain inflammatory mediators or direct effect on resident brain cells. This evidence concerns the gene CXCL13 and systemic lupus erythematosus.